We regret to announce that from this week Tony Evans will be taking an extended leave of absence from the role of CEO and Chair of Cancer Therapeutics CRC due to medical reasons. Tony has been Chair of Cancer Therapeutics since 2011 and was the CEO for three years prior to that. In late 2019, Tony stepped back into the role of CEO along with his role as Chair so that the incumbent CEO at the time, Brett Carter, could focus his attention on the establishment of the legacy organisation of the CRC – Recurve Therapeutics.
We thank Tony for his long-standing dedication to the CRC and we wish him all the best for a speedy recovery.
In the interim, Nick Gough will be stepping in to fill the role of CEO and Chair. Nick is well placed to assume this role, having been a member of the Cancer Therapeutics Board since 2014, recently as Deputy Chair and his extensive experience in the local medical research and biotech communities and within other CRCs.
Nick will be taking a leave of absence from his role as a Director of CTxONE Pty Ltd.
The team at Cancer Therapeutics CRC is otherwise unchanged and continues their unwavering commitment to the vision of the CRC and to finding cures for cancers.